

MICROBIOTA FMT in IBD

THE ROME MEETING

Con la sponsorizzazione non condizionante di

abbvie

AGpharma

ALFASIGMA

CADIGROUP®
FARMACEUTICI

HEALTHCARE
CELLTRION

GIULIANI

Johnson & Johnson

Lilly

Pfizer

NAMED
GROUP
IL NOME DELLA SALUTE
WM
Wellmicro®

Sede Congresso:

SALA ITALIA - Centro Congressi
UNIVERSITÀ CATTOLICA DEL SACRO CUORE
Largo Francesco Vito 1 - ROMA

ECM

ID Evento: 6364 - 428547

Per l'evento sono stati assegnati 7 crediti formativi E.C.M.

Figure Professionali accreditate:

BIOLOGO

INFERMIERE

FARMACISTA

FARMACISTA PUBBLICO DEL SSN

FARMACISTA TERRITORIALE

FARMACISTA DI ALTRO SETTORE

DIETISTA

MEDICO CHIRURGO

Specializzazioni:

Gastroenterologia, Medicina e chirurgia di accettazione ed urgenza,
Medicina interna, Chirurgia generale, Geriatria, Medicina Generale,
Scienza dell'Alimentazione e dietetica.

OBIETTIVO FORMATIVO:

2 LINEE GUIDA - PROTOCOLLI - PROCEDURE

[CLICCA QUI PER ISCRIVERTI](#)

PROVIDER E SEGRETERIA ORGANIZZATIVA

EVENTLAB

Via Paolo Emilio 7 - 00192 ROMA
Tel. 06.45505560
segreteria@event-lab.eu

Gemelli  1964
2024
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore

 UNIVERSITÀ
CATTOLICA
del Sacro Cuore

3rd Edition

MICROBIOTA FMT in IBD

THE ROME MEETING

December 5th-6th, 2024

SALA ITALIA - Centro Congressi
UNIVERSITÀ CATTOLICA DEL SACRO CUORE
Largo Francesco Vito, 1 - Roma

PRESIDENT
Antonio Gasbarrini

SCIENTIFIC COORDINATORS:
Franco Scalfaferrì
Loris Riccardo Lopetuso

MICROBIOTA FMT in IBD

THE ROME MEETING

December 5th-6th 2024

SALA ITALIA - Centro Congressi
UNIVERSITÀ CATTOLICA DEL SACRO CUORE
Largo Francesco Vito, 1 - Roma

PRESIDENT
Antonio Gasbarrini

SCIENTIFIC COORDINATORS:
Franco Scaldaferrri
Loris Riccardo Lopetuso

SCIENTIFIC COMMITTEE
Alessandro Armuzzi
Giovanni Cammarota
Fabio Cominelli
Sara Deleu
Gianluca Ianiro

Alfredo Papa
Theresa T. Pizarro
Maurizio Sanguinetti
Severine Vermeire

Inflammatory Bowel Diseases (IBD) in Europe affect approximately 2.5 million people, particularly young adults between the ages of 20 and 40 as well as children and adolescents: no age group is spared. In Italy, it is estimated that around 200,000 people are affected. Each year, there are between 3,000 and 5,600 new diagnoses of Ulcerative Colitis and between 1,350 and 2,000 of Crohn's Disease.

These are conditions that cause inflammation of the intestinal mucosa and can significantly impact patients' quality of life due to recurring symptoms (including bloody diarrhea, abdominal pain, fever, nausea, vomiting, etc.); sometimes, the severity of the symptoms requires hospitalization. Diagnosis is often not straightforward outside specialized centers, and it can take 2-3 years from the onset of symptoms to disease recognition. A well-organized strategy and appropriate therapy can often prevent the onset of irreversible complications. In patients with active disease, recognizing the severity level involves choosing the therapeutic strategy to try to bring the disease into remission. Various scores in the literature attempt to classify patients according to disease activity in different classes. This international event will be hosting eminent opinion leaders of the IBD scientific community. Who will be able to provide important insights, including new research on microbiota, pharmacokinetics, and future directions of therapeutic strategies

December 5th, 2024

Programme

SESSION I - MICROBIOTA, FMT IN IBD - THE ROME MEETING

Chairs: L. R. Lopetuso, F. Scaldaferrri

14.00 - 14.20 Greetings and introduction to the day | A. Gasbarrini, M. Sanguinetti

14.20 - 14.40 Gut microbiota in health and disease | Herbert Tilg

14.40 - 15.00 Computational metagenomics for the analysis of gut microbiota | F. De Maio

15.00 - 15.20 Gut microbiota testing in clinical practice | G. Ianiro

15.20 - 15.40 Discussion

SESSION II Focus on Gut microbiota in IBD

Chairs: G. Cammarota, E. Savarino

15.40 - 16.00 Microbiota imbalance in IBD | S. Vermeire

16.00 - 16.20 How the microbiota shapes the immune system in health and disease | T. T. Pizarro

16.20 - 16.40 Pharmacological and non-pharmacological modulators of gut microbiota | J. Raes

16.40 - 17.00 Discussion

17.00 - 17.30 Coffee break

SESSION III Gut microbiota in IBD: target for therapies?

Chairs: F. Cominelli, S. Vermeire

17.30 - 17.50 Mesalazine and beyond: gut microbiota interference on drug activity | A. Papa

17.50 - 18.10 Gut microbiota and IBD therapeutics: anti-TNF, anti-integrin and anti-IL12/IL23 therapeutic strategies | S. Paramsothy

18.10 - 18.30 Gut microbiota and IBD therapeutics: anti-JAKs, anti-IL23 therapeutic strategies and beyond | D. Noviello

18.30 - 18.50 Gut microbiota in drug-induced inflammatory bowel diseases: towards new predictive, diagnostic and therapeutic strategies | E. Savarino

18.50 - 19.10 Discussion

December 6th 2024

SESSION IV Gut microbiota in IBD: anything beyond available therapies?

Chairs: P. Gionchetti, L. R. Lopetuso, T. T. Pizarro

09.00 - 09.20 How diet shapes intestinal inflammation in murine models of IBD? | F. Cominelli

09.20 - 09.40 Precision nutrition and the gut microbiota | S. Deleu

09.40 - 10.00 Pre- and pro-biotics in clinical practice | G. Marasco

10.20 - 10.40 Future microbiome therapeutics | F. Facciotti

10.40 - 11.00 Discussion

11.00 - 11.30 Coffee break

SESSION V Building evidence for FMT in IBD: from trial to clinical practice

Chairs: G. Fiorino, L. Putignani, S. Vetrano

11.30 - 11.50 FMT: current evidence and future applications | J. Kupciskas

11.50 - 12.10 FMT in IBD: how to break the therapeutic ceiling? | I. Dotan

12.10 - 12.30 Methodological challenges in RCTs for complex therapies: Lessons for FMT Trials | D. Piovani

12.30 - 12.50 How to design future real life trials in IBD: lessons from pharmacological trials | L. Laterza

12.50 - 13.10 Results from the II Rome Consensus Conference on Gut Microbiota and FMT | F. Scaldaferrri, L. R. Lopetuso

13.10 - 13.30 Discussion

13.30 - 14.30 Lunch

14.30 - 16.30 II Rome Consensus Conference on Gut Microbiota and FMT - Invited Session

SCIENTIFIC COORDINATORS:

Antonio Gasbarrini, Loris Riccardo Lopetuso, Franco Scaldaferrri

EXPERT PANEL MEMBERS:

Maria Abreu, Alessandro Armuzzi, Patrizia Brigidi, Giovanni Cammarota, Fabio Cominelli, Samuel Paul Costello, Sara Deleu, Flavio De Maio, Iris Dotan, Federica Facciotti, Gionata Fiorino, Lih Godny, Ailsa Hart, Gianluca Ianiro, Tariq H Iqbal, Dai Ishikawa, Juozas Kupciskas, Giovanni Marasco, Luca Masucci, Daniele Noviello, Alfredo Papa, Sudarshan Paramsothy, Valentina Petito, Theresa T. Pizarro, Pierluigi Puca, Daniela Pugliese, Lorenza Putignani, Davide Ribaldone, Maurizio Sanguinetti, Edoardo Savarino, Harry Sokol, Herbert Tilg, Séverine Vermeire

Donors profiling

Chair: L. Putignani

Discussant: S. Deleu, V. Petito

Patients profiling

Chair: A. Armuzzi

Discussant: G. Marasco, J. Raes

Trial design

Chair: S. Vermeire

Discussant: G. Fiorino, D. Piovani

Future perspectives

Chair: G. Cammarota

Discussant: L. Godny, P. Puca